COMMUNIQUÉS West-GlobeNewswire

-
BELLUS Santé annonce la fixation du prix de son placement d’actions ordinaires de 35 millions de dollars
11/12/2018 -
Admera Health Genetic Tests are Now In-Network with CareFirst BlueCross BlueShield, Maryland, Washington D.C, and Northern Virginia
11/12/2018 -
NanoVibronix Announces Selection of Leading International Contract Manufacturer to Support Rapid Scale-up, Lower Price Points and Enhance Profitability
11/12/2018 -
Groundbreaking animal wellness company PetVivo Holdings Inc., an emerging bio-medical company, announces the formation of nonprofit PetVivo Cares
11/12/2018 -
Westleaf Cannabis is Redefining Retail Across Canada -- CFN Media
11/12/2018 -
Farmako: Cannabis distributor to become gateway to Europe
11/12/2018 -
Eve & Co Announces Product Release
11/12/2018 -
Avadel Pharmaceuticals Appoints Kevin Kotler to the Company’s Board of Directors
11/12/2018 -
Sapience Therapeutics to Present at Biotech Showcase 2019
11/12/2018 -
Cellectar Granted Japanese Patent for CLR 131
11/12/2018 -
Sarepta Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of Directors
11/12/2018 -
Medifirst Solutions to Present at the American Pain Association Conferences Focusing on Medical CBD and the Opioid Epidemic
11/12/2018 -
MyoKardia Reports Positive Data from Phase 1b Single-Ascending Dose Clinical Trial of MYK-491 in Dilated Cardiomyopathy and Systolic Heart Failure Patients
11/12/2018 -
Aptinyx to Present Preclinical Data on NMDA Receptor Modulator NYX-2925 at the American College of Neuropsychopharmacology’s Annual Meeting
11/12/2018 -
Aravive Biologics Initiates Phase 1b Portion of Phase 1b/2 Clinical Trial of AVB-S6-500 in Platinum-Resistant Recurrent Ovarian Cancer
11/12/2018 -
Arch Biopartners Forms New Subsidiary to Pursue a Phase I Trial in Australia for Metablok (LSALT Peptide)
11/12/2018 -
Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 (devimistat) in Combination with Modified FOLFIRINOX as First Line Treatment for Patients with Metastatic Pancreatic Cancer
11/12/2018 -
NexImmune Granted Key US Patent for Core E+E Technology
11/12/2018 -
ImmuCell Announces USDA Approval of Dual-Force™ First Defense®
11/12/2018
Pages